ArticleThe Journal of antimicrobial chemotherapy2026
Characterization of IMI-4 carbapenemase-producing Enterobacter sp. isolated from humans and a companion animal in French Indian Ocean territories.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCarbapenemase-producing Enterobacterales (CPE) are a significant public health concern, associated with high morbidity and mortality rates due to restricted antibiotic treatment options. Among the genetic determinants of CPE resistance, imipenemase (IMI) mediated resistance is an emerging problem in infections involving bacteria of the Enterobacter cloacae complex (ECC) and has been linked to worldwide clinical cases, including community-level outbreaks in the Indian Ocean region. Little is known about the potential role of animals as reservoirs of multidrug-resistant ECC bacteria.
objectivesCharacterize blaIMI-4 carbapenemase-producing ECC strains isolated from patients and a companion animal in the southwestern Indian Ocean region (Réunion and Mayotte islands).
methodsWe used antibiotic susceptibility testing to determine available treatment and genome sequencing to characterize resistance gene variants and mobile genetic elements carrying blaIMI-4 genes.
resultsblaIMI-4 ECC isolates are susceptible to new antibiotics active on Class A carbapenemase, notably β-lactams-inhibitors (ceftazidime-avibactam, meropenem-vaborbactam). The blaIMI-4 gene was identified on a common EcloIMEX-2 mobile integrative element in (i) ST 2370 Enterobacter sichuanensis isolated from a dog in Réunion and (ii) ST1845 Enterobacter roggenkampii clinical isolates from Réunion and Mayotte islands.
conclusionsCompanion animals may play a role in the persistence and spread of mobile genetic elements that confer carbapenem resistance in diverse Enterobacter species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.